KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data [Yahoo! Finance]
Kura Oncology, Inc. (KURA)
Last kura oncology, inc. earnings: 2/25 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kuraoncology.com/investor-relations
Company Research
Source: Yahoo! Finance
The analysis focused on patients with clear cell renal cell carcinoma (ccRCC) who had previously been treated with cabozantinib, a population that typically showed limited response to further treatment. Year to date, shares of KURA have lost 6.9% against the industry's 3.5% growth. Zacks Investment Research Image Source: Zacks Investment Research Key Highlights of KURA's FIT-001 Study In the FIT-001 study, darlifarnib is being administered at once-daily doses of 3 mg, 5 mg or 8 mg on a seven-day on and off schedule, in combination with cabozantinib, given once daily at 60 mg or 40 mg. The treatment demonstrated strong anti-tumor activity along with a manageable safety profile across different dose levels, including full-dose cabozantinib. Among 16 evaluable patients, the regimen achieved an objective response rate of 44%, while the disease control rate reached 94% across all dose levels. Tumor shrinkage was observed in 75% of patients, with reductions ranging from 32% to 4
Show less
Read more
Impact Snapshot
Event Time:
KURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KURA alerts
High impacting Kura Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
KURA
News
- Kura Oncology: Poised For A Lift With Combinations [Seeking Alpha]Seeking Alpha
- How The Kura Oncology (KURA) Narrative Is Shifting With Komzifti Launch And New Analyst Targets [Yahoo! Finance]Yahoo! Finance
- Kura Oncology, Inc. (KURA) Discusses Updated Data on Darlifarnib and Cabozantinib Combination in Advanced Renal Cell Carcinoma Transcript [Seeking Alpha]Seeking Alpha
- Kura Oncology Shares Surge Following Positive Kidney Cancer Trial Data [TheStreet.com]TheStreet.com
- Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With CabozantinibGlobeNewswire
KURA
Earnings
- 3/5/26 - Miss
KURA
Sec Filings
- 4/10/26 - Form ARS
- 4/10/26 - Form DEFA14A
- 4/10/26 - Form DEF
- KURA's page on the SEC website